MedTrace Logo

Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection

NCT02261662 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-10-10

No results posted yet for this study

Summary

This study will be conducted on 30 patients with mucocutaneous complaints and documented HCV infection. The study will be done at Tropical medicine department , Tanta university. It will be conducted between June2014 and November 2014.

The aim of the study is to assess efficacy of Ribavirin in the management of mucocutaneous extrahepatic manifestations of HCV infection.

Conditions

Interventions

DRUG

Ribavirin

A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. It will be used along with Topical steroids; Betamethasone

DRUG

Betamethasone

Topical Steroids alone will be used; Betamethasone

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Asem A Elfert, MD · Tanta Faculty of Medicine, Professor

  • Fat-heya E Assel, MD · Tanta Faculty of Medicine, Professor

  • Mohamed Y Rabei · Dr.

  • Islam S Ismail · Dr.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02261662 on ClinicalTrials.gov